Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice.
Pieper AA, Rakhmilevich AL, Spiegelman DV, Patel RB, Birstler J, Jin WJ, Carlson PM, Charych DH, Hank JA, Erbe AK, Overwijk WW, Morris ZS, Sondel PM. Pieper AA, et al. Among authors: charych dh. J Immunother Cancer. 2021 Jun;9(6):e002715. doi: 10.1136/jitc-2021-002715. J Immunother Cancer. 2021. PMID: 34172518 Free PMC article.
Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy.
Sharma M, Khong H, Fa'ak F, Bentebibel SE, Janssen LME, Chesson BC, Creasy CA, Forget MA, Kahn LMS, Pazdrak B, Karki B, Hailemichael Y, Singh M, Vianden C, Vennam S, Bharadwaj U, Tweardy DJ, Haymaker C, Bernatchez C, Huang S, Rajapakshe K, Coarfa C, Hurwitz ME, Sznol M, Hwu P, Hoch U, Addepalli M, Charych DH, Zalevsky J, Diab A, Overwijk WW. Sharma M, et al. Among authors: charych dh. Nat Commun. 2020 Jan 31;11(1):661. doi: 10.1038/s41467-020-14471-1. Nat Commun. 2020. PMID: 32005826 Free PMC article. Clinical Trial.
Maximizing cancer therapy via complementary mechanisms of immune activation: PD-1 blockade, neoantigen vaccination, and Tregs depletion.
D'Alise AM, Leoni G, De Lucia M, Langone F, Nocchi L, Tucci FG, Micarelli E, Cotugno G, Troise F, Garzia I, Vitale R, Bignone V, Di Matteo E, Bartolomeo R, Charych DH, Lahm A, Zalevsky J, Nicosia A, Scarselli E. D'Alise AM, et al. Among authors: charych dh. J Immunother Cancer. 2021 Nov;9(11):e003480. doi: 10.1136/jitc-2021-003480. J Immunother Cancer. 2021. PMID: 34824160 Free PMC article.
NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models.
Charych DH, Hoch U, Langowski JL, Lee SR, Addepalli MK, Kirk PB, Sheng D, Liu X, Sims PW, VanderVeen LA, Ali CF, Chang TK, Konakova M, Pena RL, Kanhere RS, Kirksey YM, Ji C, Wang Y, Huang J, Sweeney TD, Kantak SS, Doberstein SK. Charych DH, et al. Clin Cancer Res. 2016 Feb 1;22(3):680-90. doi: 10.1158/1078-0432.CCR-15-1631. Clin Cancer Res. 2016. PMID: 26832745
Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist.
Parisi G, Saco JD, Salazar FB, Tsoi J, Krystofinski P, Puig-Saus C, Zhang R, Zhou J, Cheung-Lau GC, Garcia AJ, Grasso CS, Tavaré R, Hu-Lieskovan S, Mackay S, Zalevsky J, Bernatchez C, Diab A, Wu AM, Comin-Anduix B, Charych D, Ribas A. Parisi G, et al. Nat Commun. 2020 Jan 31;11(1):660. doi: 10.1038/s41467-019-12901-3. Nat Commun. 2020. PMID: 32005809 Free PMC article.
Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer.
Harding TC, Long L, Palencia S, Zhang H, Sadra A, Hestir K, Patil N, Levin A, Hsu AW, Charych D, Brennan T, Zanghi J, Halenbeck R, Marshall SA, Qin M, Doberstein SK, Hollenbaugh D, Kavanaugh WM, Williams LT, Baker KP. Harding TC, et al. Sci Transl Med. 2013 Mar 27;5(178):178ra39. doi: 10.1126/scitranslmed.3005414. Sci Transl Med. 2013. PMID: 23536011
14 results